Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (412)	2/11/2000 11:52:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

V1, <<...a better Ritalin about to enter phase III.. >> They already completed pivotal PIII trial and safety (one year) should be completed by April. NDA in summer (if they don't immigrate to EU like me) and 1/2-Q 01 on market. I think that they already have deal for manufacturing, and 50:50 marketing partner (pharma or generic, chose one) should not be a problem. <<...Thalidomide derivatives in the pipeline...>> Yes, I am anxious to hear about pilot PI/II SelCID Chron's trial results. <<...opportunity to join the top tier of biotechs>> and Forbes reporter predicted bankruptcy for CELG in 98/99? What a jerk!!! Miljenko PS: Back to Bzzz... mode